日期: 2018-08-21
浏览次数: 25

Resverlogix is a late-stage clinical biotechnology company dedicated to improving and saving the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease.Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of high-risk cardiovascular disease patients who also have type 2 diabetes mellitus and low high-density lipoprotein (HDL). The current standard of care for these patients is administration of statins, of which, the two most common are Lipitor and Crestor. Despite maximized use, statins only manage approximately 30 percent of cardiovascular events. The opportunity for apabetalone is in addressing the huge remaining unmet medical need that can be attributed to other unmanaged risk factors such as inflammation. When used in combination with current treatments, apabetalone could address the 70 percent of unmet need in this patient group, specifically the residual inflammatory risk.

Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services